Ambrx Biopharma Inc. (AMAM), a clinical stage biopharmaceutical company developing Engineered Precision Biologics, has a couple of data readouts lined up for this year. The company's lead asset is ARX788, which is in three pivotal trials, dubbed ACE-Breast-02, ACE-Breast-03, and ACE-Gastric-02.
from RTT - Earnings https://ift.tt/norbPWO
via IFTTT
No comments:
Post a Comment